Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3823 combined with Abiraterone and Prednisone in mCRPC
NCT05405439Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB3823 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose limiting toxicity at 4 weeks, Recommended phase II dose at 8 weeks and 2 more. Started Aug 2022; status: terminated.
02
Drugs
TQB3823
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05405439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405439.